Verve Therapeutics Inc (VERV)

[Monksdream]

VERV new 52 week low

[Monksdream]

VERV new 52 week low

[Monksdream]

VERV 10Q due AUGUST5

[Monksdream]

VERV new 52 week low

[Monksdream]

VERV new 52 week low

[Monksdream]

VERV more new lows up ahead

[Monksdream]

VERV new 52 week low

[Monksdream]

VERV new 52 week low

[Monksdream]

VERV new 52 week low

[Monksdream]

VERV new 52 week low

[Monksdream]

VERV new 52 lo

[Firestorm22]

uh oh

[Monksdream]

VERV over $10

[fink]

Looking for an entry now

[Terpi]

Could see another nice move here is the 50 day holds into close.

[Monksdream]

VERV morning rally

[TheFinalCD]

https://cathiesark.com/

[crudeoil24]

VERV IS A GREAT $$$$$ OPPORTUNITY.

[crudeoil24]

Verve Therapeutics started at outperform with $48 stock price target at BMO Capital

[crudeoil24]

Verve Therapeutics, Inc. is a genetic medicines company, developing an approach to the care of cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines. The Company’s initial two programs target PCSK9 and ANGPTL3, respectively, genes that regulate levels of blood lipids. Its lead product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver. Reduction of PCSK9 protein in the blood improves the ability of the liver to clear LDL-C from the blood. VERVE-101 utilizes LNP-mediated delivery to target the liver and base editing technology to make a single base change at a specific site in the PCSK9 gene in order to disrupt PCSK9 protein production. It is advancing VERVE-101 initially for the treatment of heterozygous familial hypercholesterolemia. Its second program is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a key regulator of cholesterol and triglyceride metabolism.